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CASE REPORT
Occult hepatitis B reactivation following rituksimab treatment in a patient with 
Waldenström’s macroglobulinemia
Waldenström makroglobulinemili hastada rituksimab tedavisi sonrası gelişen gizli hepatit B 
reaktivasyonu
Murat Albayrak1, Harika Çelebi1, Emin Ediz Tutuncu2, Aynur Albayrak3, Vedat Aslan1
ÖZET
Anti CD 20 monoklonal antikor olan rituksimab B hücreli 
lenfomaların tedavisinde yaygın olarak kullanılmaktadır. 
Bir çok çalışmada rituksimab tedavisi sonrası hepatit B 
virüs  (HBV)  reaktivasyonu  gösterilmiştir.  Bu  vakaların 
büyük bir kısmı kronik HBV taşıyıcılarında tanımlanmış 
olmakla birlikte, gizli hepatit B virüs taşıyıcılarında reakti-
vasyon gelişebilir.
Waldenström  Makroglobulinemisi  tanısı  konulan  olgu-
muzda kemoterapi öncesi bakılan HBsAg (-) ve Anti HBc 
IgG (+) idi. Hastaya CVP (siklofosfamid, vinkristin, pred-
nizolon) kemoterapisi başlandı. Ancak klinik ve laboratuar 
olarak yanıt alınamadı ve hasta 3 kürlük CVP tedavisine 
yanıtsız kabul edildi. Hastaya ikinci basamak tedavi olarak 
R-CHOP (rituksimab, siklofosfamid, adriamisin, vinkristin 
ve prednizolon) verilmesi planlandı. 1. kür R-CHOP teda-
visi sonrası yapılan tetkiklerde aspartat aminotransferaz 
(AST) değeri: 267 U/L ve alanin aminotransferaz (ALT) 
değeri: 318 U/L olarak bulundu. Bakılan HBs Ag (+), HBV 
DNA: 56400 İU/ml ve Anti HBcIgG (+) olarak saptandı. 
Lamuvidin 100 mg/gün başlandı. Lamuvidin tedavisinin 
başlanmasından 4 hafta sonra AST ve ALT değerleri nor-
male döndü. Hasta en son olarak 4. kür R-CHOP tedavi-
sini aldı. AST ve ALT değerleri normal aralıkta olarak takip 
ediliyor. Bu durum Rituksimab sonrası gelişen gizli hepatit 
B reaktivasyonu olarak kabul edildi.
Bu vakayı sunmamızdaki amaç; Rituksimab gibi immün-
süpressif tedavi alan olgularda HBV reaktivasyonu olabi-
leceğine dikkat çekmektir.
Anahtar kelimeler: Waldenström makroglobulinemisi, ri-
tuksimab, gizli hepatit B enfeksiyonu.
ABSTRACT
The anti-CD20 monoclonal antibody rituximab has been 
used  extensively  in  the  treatment  of  B-cell  lymphoma. 
Several studies reported hepatitis B virus (HBV) reacti-
vation after rituximab. The majority of these cases have 
been described in chronic carriers of HBV, whereas re-
activation in occult hepatitis B virus (OHBV) carriers may 
occur.
The presented case with the diagnosis of Waldenström’s 
macroglobulinemia was HBsAg negative and anti HBcIgG 
positive before chemotherapy. The patient was started on 
CVP (cyclophosphamide, vincristine, prednisolone) che-
motherapy. However, no clinical or laboratory response 
was obtained and the patient was considered unrespon-
sive to three cycles of CVP therapy. Therefore R-CHOP 
(rituximab,  cyclophosphamide,  adriamycin,  vincristine 
and prednisolone) was planned as the second therapy. 
Laboratory work-up after the first cycle of R-CHOP ther-
apy revealed an aspartate aminotransferase (AST) level 
of 267 U/L and alanine aminotransferase (ALT) level of 
318 U/L. HBsAg and anti HBcIgG were positive and HBV 
DNA was 56400 IU/ml. Lamivudin 100 mg/day was start-
ed. Four weeks after the initiation of lamivudin therapy, 
ALT and AST levels returned to normal. Currently, the pa-
tient has received the fourth cycle of R-CHOP therapy. 
ALT and AST levels continue to be in normal range. This 
condition was considered to be the reactivation of OHBV 
following rituximab.
The aim of this case presentation is to call attention to 
HBV reactivation possibility in cases taking immunosu-
pressive medications like Rituximab. J Clin Exp Invest 
2012; 3(4): 541-544
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INTRODUCTION
Hepatitis  B  virus  (HBV)  reactivation  is  a  serious 
complication  of  cytotoxic  or  immunosuppressive 
therapies.  The  incidence  of  reactivation  following 
chemotherapy in chronic HBV carriers varies be-
tween 21 to 53%.1 An unknown number of subjects 
in the general population harbor occult HBV infec-
tion, i.e. the presence of HBV genomes in the liver 
in the absence of detectable amounts of HBsAg and 
even of any other conventional markers of HBV in-
fection in the blood.2 Occult HBV infection has been 
known to reactivate under immunosuppression and 
to cause episodes of acute hepatitis B.1 In this set-
ting, routine detection of HBsAg before chemother-
apy may not be sufficient.
We  have  presented  a  case  diagnosed  with 
Waldenström’s  macroglobulinemia  developing  an 
occult reactivation of hepatitis B following rituximab 
therapy  and  successfully  treated  with  lamivudin. 
This case was presented to draw attention to oc-
cult HBV infections and to state that there is an in-
creased risk of occult HBV reactivation with the ad-
dition of rituximab to CHOP therapy.
CASE REPORT
Forty-seven-year-old  male  patient  presented  with 
nose  bleeding,  fatigue  and  headache.  Physical 
examination  revealed  hepatosplenomegaly  and 
peripheral  lymphadenopathy.  Laboratory  work-up 
revealed  hemoglobin  level  of  12.8  g/dl,  platelets 
123.000/µL, c-reactive protein 20.1 mg/L (0-5), β2 
microglobulin level of 5.69 g/L (1.09-2.53) and im-
munoglobulin M (IgM) level of 37.8 g/L (0.4-2.30). 
Monoclonal gammapathy in protein electrophoresis 
and IgM kappa monoclonal gammapathy in serum-
urine immune fixation was detected. Bone marrow 
biopsy was carried out and diffuse infiltration with 
lymphoplasmocytes was reported (Figure 1 and 2). 
The patient was diagnosed as Waldenström’s Mac-
roglobulinemia. Viral markers were studied before 
induction of chemotherapy. HbsAg, anti HCV, anti 
HIV were negative and anti HBc IgG was found to 
be  positive.  CVP  chemotherapy  (cyclophospha-
mide,  vincristine  and  prednisolone)  was  started. 
Cyclophosphamide 750 mg/m2 (1 day), vincristine 
2 mg/day (1 day) and prednisolone 100 mg/day (5 
days) were given. A total of three cycles were ad-
ministered in every three weeks. However, a clini-
cal or laboratory response was not obtained. IgM 
level  was  still  high  and  monoclonal  gammapathy 
persisted  in  protein  electrophoresis.  The  patient 
was considered unresponsive to CVP therapy and 
R-CHOP  treatment  was  planned  with  rituximab 
375 mg/m2 (1 day), cyclophosphamide 750 mg/m2 
(1 day), vincristine 1.4 mg/m2 (1 day), adriamycin 
50 mg/m2 (1 day) and prednisolone 100 mg/day (5 
days) in every 21 days. Five days after the first cy-
cle of R-CHOP treatment the patient presented with 
fatigue. Laboratory work-up revealed an aspartate 
aminotransferase (AST) level of 267 U/L and ala-
nine aminotransferase (ALT) level of 318 U/L. Ab-
dominal ultrasonography was normal. HBsAg and 
anti HBcIgG were found positive and HBV DNA was 
56400 IU/ml. The patient was considered as having 
reactivation of occult hepatitis B and lamivudin 100 
mg/day was started. The ALT and AST levels of the 
patient returned to normal after four weeks of lami-
vudin treatment and the HBV DNA level was 41 IU/
ml. Chemotherapy was continued and the patient 
had received the fourth cycle of R-CHOP therapy 
with normal liver enzymes. This rare condition was 
considered to be reactivation of occult hepatitis B 
following the administration of chemotherapy.
Figure 1. Bone marrow biopsy section from a patient with 
waldenström macroglobulinemi shows an extensive dif-
fuse infiltrate (H&E, X100)
Figure 2. This clonal bone marrow disorder is morpho-
logically  characterized  by  a  neoplastic  proliferation  of 
small lymphocytes, plasma cells, and plasmacytoid lym-
phocytes (H&E, X400)Albayrak et al. Hepatitis B reactivation following rituksimab treatment 543
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DISCUSSION
Rituximab  is  a  chimeric  monoclonal  antibody 
against the protein CD20, which is commonly used 
in the treatment of B cell lymphomas.3,4 Rituximab is 
also an effective immunosuppressive agent which 
may  lead  to  HBV  replication.5  Antracyclin  based 
chemotherapy  regimens  (such  as  cyclophospha-
mide, doxorubicin, vincristine and prednisone) with 
the addition of rituximab (R-CHOP), forms the stan-
dard front line therapy in the treatment of CD 20 (+) 
B cell lymphomas.6
Rituximab has been found to induce profound 
and durable B-cell depletion. Although lysis of HBV-
infected hepatocytes is mainly mediated by CD8+ 
cytotoxic T-cell immunity, B cells may also act as 
antigen-presenting  cells  and  prime  cytotoxic  T-
cell–specific responses in HBV infection. The B cell 
depletion due to rituximab may result in defective T 
cell response to the HBV which may lead to the viral 
replication.3 This is supported by the observation of 
rituximab-induced severe or fatal cytomegalovirus 
reactivation,  parvovirus  B19  infection,  adenovirus 
infection, and Pneumocystis carini pneumonia.4
HBV reactivation is a common complication in 
HBsAg  positive  patients  undergoing  immunosup-
pressive  anticancer  therapy.  On  the  other  hand, 
HBV reactivation has previously been reported to 
be much less common in patients who had resolved 
HBV infection. However, with the recent increase in 
the use of rituximab, HBV reactivation has been in-
creasingly reported.4
Different  rates  of  HBV  reactivation  were  re-
ported following rituximab containing regimens. The 
causes  for  this  can  be  intensive  therapy,  patient 
characteristics,  genotypic  variations  in  HBV  and 
geographic variations.3
A study has evaluated HBV reactivation follow-
ing rituximab containing chemotherapy in 261 cas-
es with CD 20 (+) B cell lymphoma and occult HBV 
infection was found in 56 cases. Among these oc-
cult HBV carriers, reactivation was reported in five 
patients (8.9%).3 Similarly in the study by Fukushi-
ma et al., HBV reactivation after rituximab treatment 
was reported in only 2 (6.3%) out of 32 patients with 
occult HBV infection.7 Yeo et al. reported that there 
was an increased risk of HBV reactivation with the 
addition of rituximab to CHOP chemotherapy.4
Prophylactic use of antiviral agents before che-
motherapy is the standard approach in HBV car-
riers.  However,  there  is  no  consensus  about  the 
prophylactic use of antiviral agents in cases with 
occult HBV infections. Nevertheless, mortality rate 
increases in these patients when HBV reactivation 
occurs.8
The present data suggest that, for patients who 
are planned to receive anti B cell therapy, and are 
HBsAg negative should further be screened for anti 
HBc  and  anti  HBs.  To  prevent  HBV  reactivation 
and its associated morbidity and mortality, patients 
those found to be positive for anti HBc, particularly 
patients who are negative for anti HBs, should be 
closely monitored with HBV DNA and serum bio-
chemistry during and for at least 6 months after the 
completion  of  rituximab  therapy,  with  an  antiviral 
administered promptly on the detection of reactiva-
tion.9 However, reports using this approach have not 
been found to be universally successful, with HBV 
associated mortality still being observed, possibly 
because of a delay in the antiviral administration.10
Yeo  et  al.  recommended  prophylactic  use  of 
lamivudin up to six months after the completion of 
chemotherapy containing rituximab.4 Lamivudin is 
a safe and cost-effective antiviral agent, but it can 
induce mutations when used for a long term.11 Cur-
rently entecavir is one of the most potent antiviral 
agent  for  chronic  hepatitis  B.  But  compared  with 
Lamuvidin it is much more expensive.12
With the increasing use of rituximab and other 
novel antilymphocytic therapies for the treatment of 
lymphoma, HBV reactivation in patients who have 
resolved HBV infection will pose an increasing clini-
cal challenge, especially in endemic areas. Further 
studies with close monitoring would provide a better 
understanding of the mechanism of this condition.
In  our  opinion  in  patients  that  considered  to 
have immunosuppresive therapy like Rituximab, it 
is necessary to evaluate anti HBc IgG levels with 
HBS Ag before treatment. Prophylactic Lamuvidin 
therapy should be considered in patients with Anti 
HBc IgG (+) and HBs Ag (-) and treatment must be 
continued at least 6 months from the end of specific 
chemotherapy.
 In conclusion, rituximab containing regimens 
for the treatment of B cell lymphoma may increase 
the likelihood of HBV reactivation in patients with 
isolated anti HBc positivity. Further studies aimed 
at preventing HBV reactivation are needed. Close 
monitoring of HBV serology during therapy and pro-
phylactic or preemptive use of antiviral agents are 
recommended in high risk patients receiving ritux-
imab containing chemotherapies.Albayrak et al. Hepatitis B reactivation following rituksimab treatment 544
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